Posted by Michael Wonder on 23 Sep 2025
GLP-1 drugs Ozempic and Mounjaro close to reimbursement in diabetes care
23 Septemner 2025 - With GLP-1 receptor agonists nearing reimbursement for diabetes treatment, the Government is preparing tighter oversight and a monitoring system.
Novo Nordisk announced that the company will launch its diabetes treatment Ozempic (semaglutide) as a non-reimbursed drug starting on Thursday.
